Cordycepin Inhibition of 3-Methylcholanthrene-Induced Transformation In Vitro

Price, Paul J.; Suk, William A.; Peters, Robert L.; Martin, Carolyn E.; Bellew, Teresa M.; Huebner, Robert J.

doi:10.3181/00379727-150-39098

Cited by 10 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early in the study of cordycepin, it was observed that high doses can kill cells in culture and affect cell proliferation [ 8 , 9 ]. The idea that cordycepin may be a potential cancer treatment has led to many studies examining the doses at which cordycepin reduces cell numbers in culture.…”

Section: Resultsmentioning

confidence: 99%

A Systematic Review of the Biological Effects of Cordycepin

Radhi

Ashraf²,

Lawrence

et al. 2021

Molecules

View full text Add to dashboard Cite

We conducted a systematic review of the literature on the effects of cordycepin on cell survival and proliferation, inflammation, signal transduction and animal models. A total of 1204 publications on cordycepin were found by the cut-off date of 1 February 2021. After application of the exclusion criteria, 791 papers remained. These were read and data on the chosen subjects were extracted. We found 192 papers on the effects of cordycepin on cell survival and proliferation and calculated a median inhibitory concentration (IC50) of 135 µM. Cordycepin consistently repressed cell migration (26 papers) and cellular inflammation (53 papers). Evaluation of 76 papers on signal transduction indicated consistently reduced PI3K/mTOR/AKT and ERK signalling and activation of AMPK. In contrast, the effects of cordycepin on the p38 and Jun kinases were variable, as were the effects on cell cycle arrest (53 papers), suggesting these are cell-specific responses. The examination of 150 animal studies indicated that purified cordycepin has many potential therapeutic effects, including the reduction of tumour growth (37 papers), repression of pain and inflammation (9 papers), protecting brain function (11 papers), improvement of respiratory and cardiac conditions (8 and 19 papers) and amelioration of metabolic disorders (8 papers). Nearly all these data are consistent with cordycepin mediating its therapeutic effects through activating AMPK, inhibiting PI3K/mTOR/AKT and repressing the inflammatory response. We conclude that cordycepin has excellent potential as a lead for drug development, especially for age-related diseases. In addition, we discuss the remaining issues around the mechanism of action, toxicity and biodistribution of cordycepin.

show abstract

Section: Resultsmentioning

confidence: 99%

A Systematic Review of the Biological Effects of Cordycepin

Radhi

Ashraf²,

Lawrence

et al. 2021

Molecules

View full text Add to dashboard Cite

show abstract

“…The essential nature of leukemia virus infection in cocarcinogenesis was indicated by the failure of the virus to transform the cells when added after chemical treatment (Price et al, 1973). Furthermore, it has been demonstrated that cordycepin and typespecific anti-RLV antisera also inhibit co-carcinogenesis (Price et al, 1975(Price et al, , 1976. However, relatively little systematic experimentation has been performed to elucidate the specific role of viral components in this system.…”

mentioning

confidence: 99%

Chemical‐viral co‐carcinogenesis: Requirement for leukemia virus expression in accelerated transformation

Mishra¹,

Pant²,

Thomas³

et al. 1976

Intl Journal of Cancer

View full text Add to dashboard Cite

The essential role of Rauscher leukemia virus (RLV) multiplication in viral-chemical co-carcinogenesis was investigated by the use of ethidium bromide (EtBr) as an inhibitor of viral complementary DNA (cDNA) integration in the host genome. EtBr inhibited co-carcinogenic transformation when present at the time of RLV inoculation but was ineffective when added to preinfected cells. Inhibitors of protein synthesis, puromycin and cyclohexamide also inhibited co-carcinogenic transformation of chronically infected cells. Purified rat interferon used at a concentration which inhibited 85% of RLV production did not modify the course of co-carcinogenic transformation. The implications of these observations in terms of the possible role of the virus-specific protein (s) in the co-carcinogenic process are discussed.

show abstract

A rapid in vitro assay for carcinogenicity of chemical substances in mammalian cells utilizing an attachment‐independence endpoint 2 – assay validation

Traul

Takayama

Kachevsky

et al. 1981

J of Applied Toxicology

View full text Add to dashboard Cite

In vitro carcinogenesis assays, in mammalian cells, are proving to be a necessary part of batteries of in vitro tests for detecting potential mutagens/carcinogens. The selection of which particular test to use requires an evaluation of test reliability, repeatability, sensitivity and degree of validation. Validation is particularly important because it is an integral part of the other criteria. Attachment independence is a common characteristic of transformed cells and is often used in follow-up testing to confirm transformation. In an earlier report we described a transformation assay, the Survival Assay, which measures the acquisition of attachment independence. The Rauscher leukemia virus-infected rat embryo target cells are treated with test compound for 72 h. Cells are then transferred to petri dishes containing a bottom layer of agar/medium. After 6 days the viable cell numbers of treated and control cultures are compared. We report here the results of testing 77 additional compounds in this assay; 73 of these were tested under code. Since definitive carcinogenicity data were not available for 18 of the test compounds, it is not possible to list specific correlations with in vivo test results. None the less the assay correctly identified 44 of the 49 carcinogens and 7 of the 10 noncarcinogens in the list. The noncarcinogen status of two of the latter is, however, open to question. Thus the Survival Assay appears to provide information rapidly as to the potential carcinogenicity of a test material, even when subjected to validation testing with coded compounds.

show abstract

Cordycepin Inhibition of 3-Methylcholanthrene-Induced Transformation In Vitro

Cited by 10 publications

References 0 publications

A Systematic Review of the Biological Effects of Cordycepin

A Systematic Review of the Biological Effects of Cordycepin

Chemical‐viral co‐carcinogenesis: Requirement for leukemia virus expression in accelerated transformation

A rapid in vitro assay for carcinogenicity of chemical substances in mammalian cells utilizing an attachment‐independence endpoint 2 – assay validation

Contact Info

Product

Resources

About